Anika CEO retires after two decades; president assumes corner office | Personnel Moves – March 13, 2018

Anika Therapeutics (NSDQ:ANIK) announced this month that CEO Charles Sherwood plans to retire after working for Anika for nearly twenty years. Joseph Darling, who has been Anika’s president since July 2017, will take his place in the corner office.

Darling has previously served in executive leadership roles across an array of medtech companies like Abbott (NYSE:ABT), Baxter (NYSE:BAX) and Smith & Nephew (NYSE:SNN).

“First, I would like to thank Chuck Sherwood for his close to two decades of commitment to Anika and for establishing Anika as a global innovator in joint health and tissue repair,” chairman Joseph Bower said in prepared remarks. “Chuck Sherwood built Anika as we know it. As CEO for 15 years, he has delivered outstanding product innovation and development and operational, commercial, and financial achievements.”

Get the full story at our sister site, Drug Delivery Business News.

The post Anika CEO retires after two decades; president assumes corner office | Personnel Moves – March 13, 2018 appeared first on MassDevice.

Anika extends deal with UMass Amherst to develop rheumatoid arthritis therapy


Anika Therapeutics (NSDQ:ANIK) has inked a deal to extend its two-year-long collaboration with the Institute for Applied Life Sciences at the University of Massachusetts Amherst.

The group plans to focus its efforts on developing a novel therapeutic candidate to treat rheumatoid arthritis. Anika and UMass reported that it hopes to bring the product into clinical trials to support a potential regulatory submission.

Get the full story at our sister site, Drug Delivery Business News.

OncoSec Medical names new CEO | Personnel Moves – Nov. 9, 2017


OncoSec MedicalOncoSec Medical (NSDQ:ONCS)  announced earlier this week that the company’s co-founder, Punit Dhillon, would step down as CEO and continue to serve as president while Daniel O’Connor takes over the corner office.

O’Connor joined OncoSec’s board of directors in September this year.

“We are pleased to welcome Dan to OncoSec at this important time, and believe he is uniquely qualified to lead the company through the successful completion of its phase IIb registration directed trial, Pisces/Keynote-695 in patients with unresectable metastatic melanoma who have progressed or are progressing on an anti-PD-1 therapy,” chairman Avtar Dhillon said in prepared remarks. “Dan is a proven leader with a strong track record of success and brings exceptional strategic and operational expertise in building thriving, successful biopharma companies.”

Get the full story at our sister site, Drug Delivery Business News.

Anika touts Phase III data for Cingal knee therapy

  • ‘Radiating Shoe Sales’

    By: Vanessa Burrows Since the discovery of X-rays in the late 19th century, the technology has enhanced health care in a variety of ways. Like many cutting-edge scientific developments, however, it also has inspired uses of uncertain therapeutic value. That was the case with the shoe-fitting fluoroscope, the subject of the latest episode of FDA’s […]

  • Invetech announces senior management changes

    Invetech – provider of instrument development, custom automation and contract manufacturing – has announced refinements to its senior management structure as it continues to pursue growth in the diagnostics, connected health and cell therapy automation markets. Anthony Annibale has accepted the role of  global VP of sales, diagnostics and healthcare. Annibale is a proven product […]

  • Apple Watch detects atrial fibrillation using built-in technology

    The Apple Watch can automatically detect atrial fibrillation (AF) using its built-in heart rate sensor and artificial intelligence, according to a new study. The research used a deep neural network that was based on photoplethysmographic (PPG) sensors that are frequently found in smart watches. When paired with an artificial intelligence-based algorithm, Apple Watch’s heart rate […]

  • NAMSA announces partnership with Naglreiter

    Medical research organization NAMSA today announced a partnership with the Naglreiter medical device development organization, which focuses on medical device design, development and manufacturing. For nearly 50 years, NAMSA has focused on offering the most critical services required to accelerate time-to-market and reduce costs for medical device research clients across the world. Consistently recognized as a pioneer in […]

  • Resonetics adds applications development lab and nitinol processing to San Diego facility

    Resonetics has announced its plans to add a Lightspeed ADLTM application development lab to its manufacturing site in San Diego. The site will offer a variety of micro manufacturing tools to service medical device and diagnostics customers and will feature various laser wavelengths optimized for polymers, glass and metals. In addition, the San Diego facility […]

  • TransEnterix CEO: Robotic surgery has a big problem

    Todd Pope has been working in the surgical robotics space for over a decade. As the CEO of TransEnterix, which has developed Senhance surgical assistance device, Pope believes the surgical robotics market is about to explode. But before it can take off, Pope noted that players have to address a really big problem with robotic […]

  • Stratasys unveils multi-cell additive manufacturing platform

    Stratasys has launched its Continuous Build 3D Demonstrator multi-cell additive manufacturing platform for low-volume, continuous production. The Continuous Build 3D Demonstrator is a modular unit that has multiple 3D print cells working together through a central, cloud-based architecture. The platform is designed to create parts in a continuous manner with very little minor operator intervention. […]

  • Spectrum Plastics Group: Why the merger took place

    The M&A deal creating Spectrum Plastics Group is but the latest in a wave of consolidations taking place among medical device industry outsourcers. Mauricio Arellano, president of Spectrum’s medical division, thinks 2 trends are driving the consolidations: the need of OEMs to provide truly disruptive innovations to meet health providers needs for value-based care, and […]

  • FDA and NIH launch new clinical trial protocol writing tool

    By Stewart Eisenhart, Emergo Group US regulators at the Food and Drug Administration and the National Institutes of Health (NIH) have published a new writing tool for use in applying for regulatory approval to conduct clinical trials for medical devices and pharmaceuticals. Get the full story here at the Emergo Group’s blog. The opinions expressed […]

  • 5 officials running healthcare under Trump

    President Donald Trump’s critics complain that the president has yet to make hundreds of appointments to midlevel positions. But at least with healthcare, we’re starting to get a clearer picture of who is in charge. Just on May 10, the U.S. Senate confirmed Dr. Scott Gottlieb as FDA commissioner. Here are 5 top officials shaping […]

  • Gut microbiomes can predict non-alcoholic fatty liver disease

    There is a microbe in stool samples that can predict non-alcoholic fatty liver disease (NAFLD), according to researchers at the University of California San Diego School of Medicine. NAFLD occurs when there is a build up extra fat in liver cells that isn’t caused by alcohol, according to the American Liver Foundation. The liver has […]